Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488738 | 0.89 | F10 (0.40) | FPR1FPR2SCN9AKDM4D | |
| SCHEMBL8298740 | 0.89 | F10 (0.40) | FPR1FPR2SCN9AKDM4D | |
| SCHEMBL14488810 | 0.87 | F10 (0.42) | KDM4D | |
| SCHEMBL8302296 | 0.86 | FPR2 (0.40) | FPR1FPR2SCN9AGAANFKB1 | |
| SCHEMBL8299289 | 0.85 | FPR2 (0.40) | FPR1FPR2SCN9AKDM4DGAA | |
| SCHEMBL5936086 | 0.84 | FPR2 (0.40) | FPR1FPR2 | |
| SCHEMBL14488708 | 0.82 | F10 (0.42) | KDM4D | |
| SCHEMBL14489105 | 0.80 | F10 (0.42) | KDM4D | |
| SCHEMBL21900482 | 0.80 | FPR2 (0.41) | FPR1FPR2GAANFKB1NFKB2 | |
| SCHEMBL28376667 | 0.80 | FPR2 (0.41) | FPR1FPR2GAANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |